Sign In
Buy AKTX
$14.99
+0.355 (+2.43%)
At Close: Jun 03, 2026
Akari Therapeutics (NASDAQ:AKTX) Stock Crosses Below Two Hundred Day Moving Average of $1.73
04:42pm, Saturday, 20'th Nov 2021 Transcript Daily
Shares of Akari Therapeutics, Plc (NASDAQ:AKTX) passed below its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $1.73 and traded as low as $1.50. Akari Therapeutics shares last traded at $1.54, with a volume of 228,235 shares. The company has a market capitalization []
Akari Therapeutics, Plc (NASDAQ:AKTX) Sees Significant Increase in Short Interest
10:18am, Friday, 19'th Nov 2021 Transcript Daily
Akari Therapeutics, Plc (NASDAQ:AKTX) was the target of a significant increase in short interest during the month of October. As of October 29th, there was short interest totalling 61,300 shares, an increase of 48.8% from the October 14th total of 41,200 shares. Based on an average daily volume of 108,200 shares, the days-to-cover ratio is []
Akari Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Clinical Progress
08:30am, Wednesday, 22'nd Sep 2021
NEW YORK and LONDON, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and
NEW YORK and LONDON, Sept. 10, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and
Akari Therapeutics to Present at the H.C. Wainwright Global Investment Conference
07:00am, Tuesday, 07'th Sep 2021
NEW YORK and LONDON, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and
Akari Therapeutics Announces Private Placement
09:15am, Wednesday, 07'th Jul 2021
NEW YORK and LONDON, July 07, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX) (“Akari” or the “Company”), a biopharmaceutical company focused on innovative therapeutics to t
Akari Therapeutics Reports Q1 2021 Financial Results and Highlights Recent Clinical Progress
04:01pm, Tuesday, 29'th Jun 2021
NEW YORK and LONDON, June 29, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and
Akari Therapeutics' Nomacopan Secures Expediated Review Tag For Blistering Skin Disorder
10:25am, Wednesday, 28'th Apr 2021
The FDA has granted Fast Track designation to Akari Therapeutics Plc's (NASDAQ: AKTX) nomacopan to treat patients with moderate and severe Bullous Pemphigoid (BP). Nomacopan has also been granted
Akari Therapeutics Reports Full Year 2020 Financial Results and Highlights Recent Clinical Progress
06:40pm, Tuesday, 20'th Apr 2021
NEW YORK and LONDON, April 20, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and
Akari Therapeutics Announces Initiation of Pivotal Phase III Trial of Nomacopan in Bullous Pemphigoid (BP)
10:16am, Monday, 12'th Apr 2021
FDA investigational new drug application (IND) now open
Study of porcine model of blast injury and haemorrhagic shock underway with USAISR as part of the development of a clinical path for the use of nomacopan to treat trauma Study of porcine model of blas
Akari Therapeutics' PASylated Nomacopan Shows Promising Action In Animal Studies
01:41pm, Thursday, 25'th Feb 2021
Akari Therapeutics Plc (NASDAQ: AKTX) announces new data from PASylated nomacopan published in the journal CELLS. In a non-infectious allergic uveitis animal model, PAS-nomacopan reduced VEGF by m
Akari Therapeutics Adds Histamine Inhibitor Votucalis to Pipeline to treat Neuropathic Pain and Dermatological Disease
09:29am, Monday, 01'st Feb 2021
NEW YORK and LONDON, Feb. 01, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and
Akari Therapeutics to Participate in Two January Virtual Investor Conferences
09:32am, Wednesday, 06'th Jan 2021
NEW YORK and LONDON, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and
Akari Therapeutics Reports Third Quarter 2020 Financial Results and Highlights Recent Clinical Progress
09:00am, Friday, 11'th Dec 2020
NEW YORK and LONDON, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and
